Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 309Oxaliplatin 260Leucovorin 234Capecitabine 198Irinotecan 147Gemcitabine 128Cisplatin 126Bevacizumab 119Radiotherapy 72Paclitaxel 64Folfox protocol 56Cetuximab 56Drug Therapy 46Sorafenib 45Docetaxel 42S 1 (combination) 40Chemotherapy, Adjuvant 38Neoadjuvant Therapy 37pembrolizumab 36130-nm albumin-bound paclitaxel 28Surgical Procedures, Operative 27regorafenib 25lenvatinib 24XELOX 24Panitumumab 24Radiation 23Nivolumab 23atezolizumab 22Carboplatin 22trifluridine tipiracil drug combination 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × gastrin immunogen × Gastrointestinal × Clear all
NCT00020787 2020-08-03

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

Jonsson Comprehensive Cancer Center

Phase 3 Completed
8 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT00044031 2014-04-17

Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma

Cancer Advances Inc.

Phase 3 Completed
394 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡